Literature DB >> 13521062

Efficacy of and indications for use of adenovirus vaccine.

M R HILLEMAN.   

Abstract

Keywords:  ADENOVIRUS INFECTIONS/immunology

Mesh:

Substances:

Year:  1958        PMID: 13521062      PMCID: PMC1551483          DOI: 10.2105/ajph.48.2.153

Source DB:  PubMed          Journal:  Am J Public Health Nations Health        ISSN: 0002-9572


× No keyword cloud information.
  22 in total

1.  Isolation and typing of adenoviruses recovered from military recruits with acute respiratory disease in The Netherlands.

Authors:  J VAN DER VEEN; G KOK
Journal:  Am J Hyg       Date:  1957-03

2.  new type of APC virus from epidemic keratoconjunctivitis.

Authors:  E JAWETZ; S KIMURA; A N NICHOLAS; P THYGESON; L HANNA
Journal:  Science       Date:  1955-12-16       Impact factor: 47.728

3.  Appraisal of occurrence of adenovirus-caused respiratory illness in military populations.

Authors:  M R HILLEMAN; R L GAULD; R L BUTLER; R A STALLONES; C L HEDBERG; M S WARFIELD; S A ANDERSON
Journal:  Am J Hyg       Date:  1957-07

4.  Efficacy of trivalent adenovirus (APC) vaccine in naval recruits.

Authors:  J A BELL; M J HANTOVER; R J HEUNER; C G LOOSLI
Journal:  J Am Med Assoc       Date:  1956-08-18

5.  Etiology of acute respiratory disease among service personnel at Fort Ord, California.

Authors:  T O BERGE; B ENGLAND; C MAURIS; H E SHUEY; E H LENNETTE
Journal:  Am J Hyg       Date:  1955-11

6.  Studies on acute respiratory illness in naval recruits, with emphasis on the adenoviruses (APC-RI).

Authors:  M FRIEDMAN; J T GRAYSTON; C G LOOSLI; W E PIERCE; J E WHITESIDE; R L WOOLRIDGE
Journal:  J Infect Dis       Date:  1956 Sep-Oct       Impact factor: 5.226

7.  Prevention of acute respiratory illness in recruits by adenovirus (RI-APC-ARD) vaccine.

Authors:  M R HILLEMAN; R A STALLONES; R L GAULD; M S WARFIELD; S A ANDERSON
Journal:  Proc Soc Exp Biol Med       Date:  1956-06

8.  Adenoviruses: group name proposed for new respiratory-tract viruses.

Authors:  J F ENDERS; J A BELL; J H DINGLE; T FRANCIS; M R HILLEMAN; R J HUEBNER; A M PAYNE
Journal:  Science       Date:  1956-07-20       Impact factor: 47.728

9.  Grouping and occurrence of RI (prototype RI-67) viruses.

Authors:  M R HILLEMAN; J H WERNER; M T STEWART
Journal:  Proc Soc Exp Biol Med       Date:  1955-12

10.  Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture.

Authors:  W P ROWE; R J HUEBNER; L K GILMORE; R H PARROTT; T G WARD
Journal:  Proc Soc Exp Biol Med       Date:  1953-12
View more
  7 in total

1.  II. EFFICACY OF ADJUVANT AND AQUEOUS ADENOVIRUS VACCINES IN PREVENTION OF NAVAL RECRUIT RESPIRATORY DISEASE.

Authors:  L F MILLER; R O PECKINPAUGH; T R ARLANDER; W E PIERCE; E A EDWARDS; P DEBERRY; I A PHILLIPS; M J ROSENBAUM
Journal:  Am J Public Health Nations Health       Date:  1965-01

2.  Trial of adenovirus vaccine in Royal Air Force recruits.

Authors:  J S WILSON; P J GRANT; D L MILLER; C E TAYLOR; J C McDONALD
Journal:  Br Med J       Date:  1960-04-09

Review 3.  Vaccine development for human mastadenovirus.

Authors:  Shiying Chen; Xingui Tian
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006.

Authors:  Gregory C Gray; Troy McCarthy; Mark G Lebeck; David P Schnurr; Kevin L Russell; Adriana E Kajon; Marie L Landry; Diane S Leland; Gregory A Storch; Christine C Ginocchio; Christine C Robinson; Gail J Demmler; Michael A Saubolle; Sue C Kehl; Rangaraj Selvarangan; Melissa B Miller; James D Chappell; Danielle M Zerr; Deanna L Kiska; Diane C Halstead; Ana W Capuano; Sharon F Setterquist; Margaret L Chorazy; Jeffrey D Dawson; Dean D Erdman
Journal:  Clin Infect Dis       Date:  2007-09-27       Impact factor: 9.079

5.  The role of adenovirus in respiratory tract infections.

Authors:  Anjali N Kunz; Martin Ottolini
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

Review 6.  Matrix and backstage: cellular substrates for viral vaccines.

Authors:  Ingo Jordan; Volker Sandig
Journal:  Viruses       Date:  2014-04-11       Impact factor: 5.048

7.  A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7.

Authors:  Jingao Guo; Youbin Zhang; Yan Zhang; Chao Zhang; Caihong Zhu; Man Xing; Xiang Wang; Dongming Zhou
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.